Search results for "LIVER METASTASES"

showing 3 items of 13 documents

Treatment sequence of synchronously (liver) metastasized colon cancer

2016

No standards for staging, systemic therapy or the timing of an operation are defined for patients newly diagnosed with synchronous metastases and a primary in the colon. An expert group of radiologists, medical, radiation and surgical oncologists therefore came together to discuss staging and treatment sequence for these patients and came up with a recommendation based on current evidence of potential therapeutic options. The discussion was organized to debate recommendations centred on 5 topics and therefore the position paper is built upon these titles and their subtitles. Editrice Gastroenterologica Italiana S.r.l.

Oncologymedicine.medical_specialtyColonColorectal cancermedicine.medical_treatment030230 surgeryTreatment sequenceSystemic therapy03 medical and health sciencesLiver metastases0302 clinical medicinePharmacotherapyDrug TherapyInternal medicinemedicineHepatectomyHumansCombined Modality TherapyTreatment optionsNeoplasm StagingHepatologybusiness.industryGeneral surgeryLiver NeoplasmsGastroenterologyAntineoplastic Protocolsmedicine.diseaseCombined Modality TherapyExpert groupColorectal cancerLiver030220 oncology & carcinogenesisPosition paperHepatectomyColorectal NeoplasmsbusinessSynchronous presentation
researchProduct

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

2022

Abstract Background Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. Methods This substudy of the prospective RAXO trial included 906 patients recruited between 2011 and 2018. We evaluated repeated centralised resectability assessment, conversion/resection rates and overall survival (OS), according to RAS and BRAF status. Results Patients included 289 with RAS and BRAF wild-type (RAS and BRAFwt), 529 with RAS mutated (RASmt) and 88 with BRAF mutated (BRAFmt) mCRC. Metastatic prevalence varied between the RAS and BRAFwt/RASmt/BRAFmt groups,…

Proto-Oncogene Proteins B-rafCancer ResearchBEVACIZUMAB3122 Cancerscolorectal cancerbiomarkkerit3121 Internal medicineleikkaushoitoLIVER METASTASESetäpesäkkeetsurgical oncologyKRASHumansmetastasisProspective StudiesFOLFOXIRIpaksusuolisyöpäCancer och onkologiRectal NeoplasmsCOLON-CANCERMetastasectomyennusteetCHEMOTHERAPYOncologysyöpägeenithoitotuloksetCancer and OncologyColonic NeoplasmsMutationSURVIVALsyöpätauditonkologiaColorectal Neoplasmsprognostic markers
researchProduct

[Role of loco-regional treatments for patients with breast cancer liver metastases].

2009

Settore MED/06 - Oncologia Medicaliver metastases from breast cancerhepatic resectionloco-regional treatment radio-frequency ablation
researchProduct